Cardioprotection against Heart Failure by Shenfu Injection via TGF-βSmads Signaling Pathway

الملخص EN

Objective.

To explore the potential cardioprotective mechanism of Shenfu injection (SFI) against heart failure (HF) by attenuating myocardial fibrosis and cardiac remodeling.

Methods and Results.

Four weeks after myocardial infarction (MI), adult male Sprague Dawley rats were randomized for 4-week treatment with Valsartan, SFI, or vehicle.

Echocardiography and hemodynamics were applied to evaluate cardiac functions.

Myocardia of coronary artery ligated (CAD) rats were observed to investigate changes in cardiac structure and function.

Our findings suggest that treatment with SFI could inhibit progression of myocardial fibrosis and attenuate cardiac remodeling.

In addition, SFI decreased expression of Smad2 and Smad3, while increasing the expression of Smad7 through regulation of TGF-β/Smads signaling pathway.

Conclusion.

Treatment with SFI in Sprague Dawley rats improves ventricular structure and function and reduces cardiac fibrosis by ameliorating TGF-β/Smads signaling pathway after ventricular remodeling.